Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Add To Watchlist

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Advancements in PC Treatment: Biotech Innovation & Optimism

View:

Post by Noteable on Sep 20, 2023 7:44pm

Advancements in PC Treatment: Biotech Innovation & Optimism

September 19, 2023 - Advancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimism

For reference, pelareorep’s ORR of 69% was recognized as delivering nearly triple the average ORR of ~25% reported in historical control trials evaluating gemcitabine in combination with nab-paclitaxel in pancreatic cancer.

SEA-CD40 developer Seagen Inc. (NASDAQ:SGEN) saw its own combo of the drug with gemcitabine, nab-paclitaxel and pembrolizumab demonstrate efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

The SEA-CD40 combo showed a total confirmed ORR of 44%, with comparable response rates observed at both evaluated dose levels of SEA-CD40.

https://www.baystreet.ca/stockstowatch/16016/Advancements-in-Pancreatic-Cancer-Treatment-Biotech-Innovations-and-Rising-Optimism16016

261

Comment

Comment by Noteable on Sep 20, 2023 7:46pm

"AEs leading to treatment discontinuation included immune-mediated lung disease (8%, n = 3) and septic shock (3%, n = 1) with SEA-CD40 at 10 µg/kg and colitis (5%, n = 1) and portal vein thrombosis (5%, n = 1) with SEA-CD40 at 30 µg/kg."

154

Comment